Janus Kinase Inhibitors and Body Weight: Current Evidence and Potential
Krasimir Kraev, Yordanka Basheva-Kraeva, Maria Uchikova, Petar Uchikov, Bozhidar Hristov, Siyana Valova, Mladen Doykov, Desislav Stanchev, Atanas Boyukliev, Zguro Batalov · 2026
Read Janus Kinase Inhibitors and Body Weight: Current Evidence and Potential by Krasimir Kraev, Yordanka Basheva-Kraeva, Maria Uchikova, Petar Uchikov, Bozhidar Hristov, Siyana Valova, Mladen Doykov, Desislav Stanchev, Atanas Boyukliev, Zguro Batalov (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13117252.txt.
Description
Janus kinase (JAK) inhibitors have become an important therapeutic option for a wide range of immune-mediated inflammatory diseases. By targeting intracellular cytokine signaling through inhibition of the JAK–STAT pathway, these agents provide effective suppression of multiple inflammatory cascades. Alongside their growing clinical use, changes in body weight—particularly weight gain—have recently been reported in clinical practice.
Catalog record
| CREATOR | Krasimir Kraev, Yordanka Basheva-Kraeva, Maria Uchikova, Petar Uchikov, Bozhidar Hristov, Siyana Valova, Mladen Doykov, Desislav Stanchev, Atanas Boyukliev, Zguro Batalov |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |